Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elsamitrusin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Elsamitrusin | DRUG | - |
Inclusion Criteria: * Histologically confirmed NHL both B and T-cell that is refractory to or has relapsed after standard therapy or for which there is no known effective treatment. * CT or MRI scans confirming measurable tumor size (lymph node must be \>1.0 cm in its longest transverse diameter). ...
Elsamitrusin is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It has been evaluated specifically in patients with relapsed or refractory Non-Hodgkin's Lymphoma. The drug is not approved for any indication and remains in clinical development.
Elsamitrusin is being developed by Assertio Holdings, Inc., which trades under the ticker ASRT. The company is responsible for the clinical program evaluating the drug in Non-Hodgkin's Lymphoma.
Elsamitrusin is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with relapsed or refractory Non-Hodgkin's Lymphoma. There are currently no active trials listed for this drug.
Elsamitrusin has been studied in a single Phase 2 clinical trial, NCT00184080, titled "Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma." The trial was completed, enrolled 7 patients, and was conducted in the United States.
Yes, Elsamitrusin is also known as Elsamitrucin, and the trial identifier SPP 28090 refers to the same agent. The alternative spelling Elsamitrucin appears in the clinical trial title for NCT00184080.